bioAffinity Technologies, Inc. Finance Lease, Right-of-Use Asset, Amortization
bioAffinity Technologies, Inc. (BIAF) reported Finance Lease, Right-of-Use Asset, Amortization of $24.64 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-07
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $24.64K, a 54.52% decline year-over-year.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $75.53K, a 21.52% decline year-over-year.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $70.94K, a 26.29% decline year-over-year.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $54.18K, a 43.71% decline year-over-year.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $275.53K, a 28.43% decline from fiscal 2024.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $384.97K, a 200.00% increase from fiscal 2023.
- bioAffinity Technologies, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $128.32K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 6 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $24.64K 10-Q · filed 2026-08-07 | $100.17K 10-Q · filed 2026-08-07 | $171.10K derived: sum of 3 quarters · filed 2026-08-07 | $225.28K derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $75.53K 10-Q · filed 2026-05-11 | $146.46K derived: sum of 2 quarters · filed 2026-05-11 | $200.64K derived: sum of 3 quarters · filed 2026-05-11 | $254.82K derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $70.94K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $125.11K derived: sum of 2 quarters · filed 2026-03-16 | $179.29K derived: sum of 3 quarters · filed 2026-08-07 | $275.53K 10-K · filed 2026-03-16 | ||
| 2025-09-30 | $54.18K 10-Q · filed 2025-11-14 | $108.35K derived: sum of 2 quarters · filed 2026-08-07 | $204.60K 10-Q · filed 2025-11-14 | $300.84K derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $54.18K 10-Q · filed 2026-08-07 | $150.42K 10-Q · filed 2026-08-07 | $246.66K derived: sum of 3 quarters · filed 2026-08-07 | $342.90K derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $96.24K 10-Q · filed 2026-05-11 | $192.49K derived: sum of 2 quarters · filed 2026-05-11 | $288.73K derived: sum of 3 quarters · filed 2026-05-11 | $513.29K derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $96.24K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $192.49K derived: sum of 2 quarters · filed 2026-03-16 | $417.05K derived: sum of 3 quarters · filed 2026-03-16 | $384.97K 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $96.24K 10-Q · filed 2025-11-14 | $320.81K derived: sum of 2 quarters · filed 2025-11-14 | $288.73K 10-Q · filed 2025-11-14 | $513.30K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $224.57K 10-Q · filed 2025-08-14 | $96.24K 10-Q · filed 2024-08-14 | $320.81K 10-Q · filed 2025-08-14 | $192.49K 10-Q · filed 2024-08-14 | $417.05K derived: sum of 3 quarters · filed 2025-08-14 | $449.13K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $96.24K 10-Q · filed 2025-05-15 | $192.49K derived: sum of 2 quarters · filed 2025-05-15 | $224.57K derived: sum of 3 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $96.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $128.32K derived: sum of 2 quarters · filed 2025-03-31 | $128.32K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $32.08K 10-Q · filed 2024-11-14 | $32.08K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |